Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMCMDVR)

Drug Name
Triptolide Drug Info
Synonyms
triptolide; 38748-32-2; Triptolid; PG490; UNII-19ALD1S53J; NSC 163062; CHEMBL463763; CHEBI:9747; 19ALD1S53J; C20H24O6; PG-490; CPD000466307; Triptolide, Tripterygium wilfordii; (-)-Triptolide; PG 490; Trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-c)furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-; SMR000466307; NSC163062; Triptolide, 1; Triptolide(PG490)/; AC1Q6AXN; BSPBio_001595; KBioGR_000315; KBioSS_000315
Cross-matching ID
PubChem CID
107985
ChEBI ID
CHEMBL463763
CAS Number
CAS 38748-32-2
TTD Drug ID
D0I6LH
INTEDE Drug ID
DR1904

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Oxidative phosphorylation 2.63 0.00e+0 93/133 (69.92%) ATP6AP1;NDUFA7;NDUFS7;...
Lysosome 2.39 0.00e+0 115/128 (89.84%) ATP6AP1;AP3S1;CTSK;...
Phagosome 2.27 0.00e+0 118/152 (77.63%) HLA-DQA1;ATP6AP1;THBS2;...
Diabetic cardiomyopathy 2.27 0.00e+0 162/203 (79.8%) COL3A1;COL1A2;NDUFA7;...
Peroxisome 2.26 0.00e+0 72/82 (87.8%) IDH2;HSD17B4;SCP2;...
Citrate cycle (TCA cycle) 2.20 0.00e+0 30/30 (100%) IDH2;PCK1;SUCLG2;...
Propanoate metabolism 2.19 0.00e+0 30/34 (88.24%) ECHS1;SUCLG2;ALDH6A1;...
Pyruvate metabolism 2.19 0.00e+0 41/47 (87.23%) GLO1;ALDH7A1;ACYP2;...
Valine, leucine and isoleucine degradation 2.15 0.00e+0 42/48 (87.5%) ACADM;OXCT1;ALDH7A1;...
Retrograde endocannabinoid signaling 2.13 0.00e+0 118/148 (79.73%) GNG10;NDUFA7;NDUFS7;...
Fatty acid degradation 2.11 0.00e+0 40/43 (93.02%) ACADM;ALDH7A1;HADH;...
Fatty acid elongation 2.10 0.00e+0 19/27 (70.37%) PPT1;HADH;HADHB;...
Pentose phosphate pathway 2.06 8.59e-4 25/30 (83.33%) TKTL1;PFKL;GPI;...
Thermogenesis 2.05 7.98e-4 173/232 (74.57%) NDUFA7;NDUFS7;NDUFA3;...
Other glycan degradation 1.99 7.45e-4 13/18 (72.22%) MAN2B1;AGA;HEXA;...
Glycosaminoglycan degradation 1.98 1.40e-3 19/19 (100%) HEXA;HEXB;GUSB;...
Parkinson disease 1.93 3.29e-3 176/249 (70.68%) NDUFA7;MAOA;NDUFS7;...
Glycine, serine and threonine metabolism 1.92 3.10e-3 31/40 (77.5%) MAOA;ALDH7A1;GAMT;...
Vibrio cholerae infection 1.91 2.94e-3 44/50 (88%) ATP6AP1;ATP6V0E2;ATP6V0B;...
Viral myocarditis 1.90 2.79e-3 53/60 (88.33%) HLA-DQA1;EIF4G3;SGCB;...
ECM-receptor interaction 1.90 2.66e-3 80/88 (90.91%) COL1A2;THBS2;COL6A3;...
Biosynthesis of unsaturated fatty acids 1.88 2.54e-3 21/27 (77.78%) HSD17B4;SCP2;ACOT7;...
Glycolysis / Gluconeogenesis 1.87 3.40e-3 56/67 (83.58%) ALDH7A1;PFKL;PCK1;...
Tryptophan metabolism 1.86 3.26e-3 35/42 (83.33%) MAOA;ALDH7A1;HADH;...
Complement and coagulation cascades 1.86 3.13e-3 76/85 (89.41%) PLAT;F2R;CFI;...
Various types of N-glycan biosynthesis 1.82 4.30e-3 26/39 (66.67%) DDOST;DAD1;HEXA;...
Renin-angiotensin system 1.82 4.96e-3 20/23 (86.96%) ATP6AP2;PRCP;AGT;...
Alanine, aspartate and glutamate metabolism 1.81 7.18e-3 27/37 (72.97%) ALDH5A1;GLUD2;ALDH4A1;...
Glyoxylate and dicarboxylate metabolism 1.79 6.93e-3 23/30 (76.67%) MDH1;PCCB;ACO2;...
Type I diabetes mellitus 1.75 1.01e-2 38/43 (88.37%) HLA-DQA1;HLA-C;HLA-F;...
Ferroptosis -1.66 4.43e-2 36/41 (87.8%) SLC39A14;FTH1;SLC3A2;...
ErbB signaling pathway -1.70 3.01e-2 79/85 (92.94%) RPS6KB1;ABL2;ELK1;...
mRNA surveillance pathway -1.72 2.76e-2 71/98 (72.45%) ACIN1;CPSF7;FIP1L1;...
FoxO signaling pathway -1.72 2.69e-2 118/131 (90.08%) GRB2;GADD45A;PDPK1;...
Estrogen signaling pathway -1.79 7.34e-3 119/137 (86.86%) KRT10;KRT17;PIK3CA;...
MAPK signaling pathway -1.80 8.08e-3 272/294 (92.52%) MAP3K11;ANGPT1;LAMTOR3;...
Cell cycle -1.84 3.99e-3 110/124 (88.71%) MCM3;CDC6;SFN;...
Transcriptional misregulation in cancer -1.86 3.37e-3 158/192 (82.29%) GADD45A;TFE3;ELANE;...
TNF signaling pathway -1.87 2.56e-3 103/112 (91.96%) PIK3CD;CASP7;CFLAR;...
RNA transport -1.89 1.50e-3 128/186 (68.82%) EIF3G;EIF3D;EIF4A2;...
Legionellosis -1.90 1.79e-3 51/57 (89.47%) NFKB1;TLR5;TNF;...
IL-17 signaling pathway -1.99 0.00e+0 84/94 (89.36%) TRAF6;CXCL6;NFKB1;...
MicroRNAs in cancer -2.08 0.00e+0 146/310 (47.1%) SOS2;ROCK1;NFKB1;...
Ribosome biogenesis in eukaryotes -2.29 0.00e+0 52/108 (48.15%) POP4;MDN1;NOL6;...
Spliceosome -2.31 0.00e+0 101/150 (67.33%) SRSF6;SNU13;ACIN1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 0.08uM 6H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 15uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.002uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 2.22uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 0.08uM 6H
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 0.08uM 6H
MDST8 CVCL_1400 Homo sapiens 0.08uM 6H
NCI-H508 CVCL_1561 Homo sapiens 0.08uM 6H
SNU-1040 CVCL_5001 Homo sapiens 0.08uM 6H
SNU-C4 CVCL_5008 Homo sapiens 0.08uM 6H
SNU-C5 CVCL_5009 Homo sapiens 0.08uM 6H
SW480 CVCL_0546 Homo sapiens 0.08uM 6H
SW620 CVCL_0547 Homo sapiens 0.08uM 6H
SW948 CVCL_0550 Homo sapiens 0.08uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 0.08uM 6H
HT115 CVCL_1294 Homo sapiens 0.08uM 6H
RKO CVCL_0504 Homo sapiens 0.08uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 0.08uM 6H
SNG-M CVCL_1707 Homo sapiens 0.08uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 0.08uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.08uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.002uM - 10uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 0.08uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 0.08uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 0.08uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 0.08uM 6H
T3M-10 CVCL_1729 Homo sapiens 0.08uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 0.08uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 0.08uM 6H
HCC515 CVCL_5134 Homo sapiens 0.08uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 0.08uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 0.08uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 0.08uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 0.08uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 0.08uM 6H
OV7 CVCL_1623 Homo sapiens 0.08uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 0.08uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 0.08uM 6H
RMUG-S CVCL_1666 Homo sapiens 0.08uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 0.08uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 0.08uM 6H, 24H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 0.08uM 6H
PL-21 CVCL_2161 Homo sapiens 0.08uM 6H
SKM-1 CVCL_0010 Homo sapiens 0.08uM 6H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 0.125uM 24H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 0.08uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 0.08uM - 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 0.08uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 0.08uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 0.08uM 6H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 10uM 24H